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A comprehensive literature search was performed to collate evidence of mitochondrial
dysfunction in autism spectrum disorders (ASDs) with two primary objectives. First, features
of mitochondrial dysfunction in the general population of children with ASD were identified.
Second, characteristics of mitochondrial dysfunction in children with ASD and concomitant
mitochondrial disease (MD) were compared with published literature of two general
populations: ASD children without MD, and non-ASD children with MD. The prevalence of
MD in the general population of ASD was 5.0% (95% confidence interval 3.2, 6.9%), much
higher than found in the general population (B0.01%). The prevalence of abnormal biomarker
values of mitochondrial dysfunction was high in ASD, much higher than the prevalence of MD.
Variances and mean values of many mitochondrial biomarkers (lactate, pyruvate, carnitine and
ubiquinone) were significantly different between ASD and controls. Some markers correlated
with ASD severity. Neuroimaging, in vitro and post-mortem brain studies were consistent with
an elevated prevalence of mitochondrial dysfunction in ASD. Taken together, these findings
suggest children with ASD have a spectrum of mitochondrial dysfunction of differing severity.
Eighteen publications representing a total of 112 children with ASD and MD (ASD/MD) were
identified. The prevalence of developmental regression (52%), seizures (41%), motor delay
(51%), gastrointestinal abnormalities (74%), female gender (39%), and elevated lactate (78%)
and pyruvate (45%) was significantly higher in ASD/MD compared with the general ASD
population. The prevalence of many of these abnormalities was similar to the general
population of children with MD, suggesting that ASD/MD represents a distinct subgroup of
children with MD. Most ASD/MD cases (79%) were not associated with genetic abnormalities,
raising the possibility of secondary mitochondrial dysfunction. Treatment studies for ASD/MD
were limited, although improvements were noted in some studies with carnitine, co-enzyme
Q10 and B-vitamins. Many studies suffered from limitations, including small sample sizes,
referral or publication biases, and variability in protocols for selecting children for MD workup,
collecting mitochondrial biomarkers and defining MD. Overall, this evidence supports the
notion that mitochondrial dysfunction is associated with ASD. Additional studies are needed
to further define the role of mitochondrial dysfunction in ASD.
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Introduction
Autistic disorder, Asperger syndrome and pervasive
developmental disorder-not otherwise specified com-
prise a heterogeneous group of neurodevelopmental
disorders known as autism spectrum disorders
(ASDs). ASDs are behaviorally defined by impair-
ments in communication and social interaction
along with restrictive and repetitive behaviors.
1 An
estimated 1 out of 110 individuals in the United
States is currently affected with ASD, with a male-to-
female ratio of 4.5:1.
2 The etiology of ASD is not
known in most cases, but a genetic component,
possibly involving 15 or more loci, is widely accepted
to contribute to the development of ASD.
3 However,
the robust phenotypic and genotypic heterogeneity
among individuals with ASD
4,5 has limited the case
for a purely genetic etiology.
6,7 Indeed, it is becoming
apparent that many children with ASD have asso-
ciated underlying medical comorbidities, such as
epilepsy, sleep disruption, mitochondrial dysfunction
and gastrointestinal (GI) abnormalities.
8–13
Mitochondrial dysfunction has been impli-
cated in several psychiatric
14,15 and neurological
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23
hypothesized that individuals with ASD may have
an abnormality in carbohydrate metabolism, and in
1998 Lombard
24 proposed that ASD may be a disorder
of impaired mitochondrial function. Over the past
decade, evidence has accumulated that some indivi-
duals with ASD have concomitant mitochondrial
dysfunction, and some have proposed a ‘mitochon-
drial autism’ subgroup.
25 Several review articles have
been recently published concerning mitochondrial
dysfunction in ASD.
9,26–28 However, to date, neither a
systematic comprehensive review nor a meta-analysis
of this recently evolving literature has been pub-
lished. In this paper, we systematically review the
evidence for mitochondrial dysfunction in ASD with
the following specific objectives:
  To calculate the prevalence of mitochondrial
dysfunction and clinical, biochemical, histological,
and genetic markers of mitochondrial dysfunction
in the general population of children with ASD.
  To calculate the effect size of the differences in the
values of biochemical markers of mitochondrial
dysfunction between the general population of
children with ASD and control groups.
  To examine the clinical, biochemical, histological
and genetic characteristics of children diagnosed
with mitochondrial disease (MD) or mitochondrial
dysfunction and concomitant ASD (referred to
hereafter as ASD/MD) and compare these charac-
teristics with the general ASD population and to
the general childhood MD population.
  To review studies examining the prevalence of ASD
or autistic features in children with MD.
  To review studies correlating biomarker values
of mitochondrial dysfunction with the severity of
ASD symptoms.
  To review animal models of ASD with abnormal
energy pathways.
  To examine treatments of mitochondrial dysfunc-
tion in children with ASD.
Before presenting this analysis, we provide an
overview of the importance of mitochondrial function
in health and disease, with reference to mechanisms
that overlap biochemical abnormalities associated
with ASD. We also briefly discuss the standardized
methods for diagnosing MD.
Mitochondrial function in health and disease
Mitochondria are distinct cellular organelles that
generate adenosine triphosphate (ATP), the energy
carrier in most mammalian cells, from adenosine
diphosphate by oxidizing glucose and fatty acids
(for a review, see Haas et al.
29). Acetyl-CoA is a key
intermediate generated from the oxidation of glucose
and fatty acids that is further metabolized by the
tricarboxylic acid (TCA) cycle. The TCA cycle
produces reduced flavin adenine dinucleotide and
reduced nicotinamide adenine dinucleotide. Reduced
nicotinamide adenine dinucleotide and reduced
flavin adenine dinucleotide transport energy to the
mitochondrial electron transport chain (ETC), a series
of reactions known as oxidative phosphorylation.
Mitochondria contain two plasma membranes, an
inner and an outer membrane. The ETC is located
in the inner mitochondrial membrane and consists
of five multi-subunit enzyme complexes (complexes
I through V) and two electron carriers (ubiquinone,
also known as co-enzyme Q10, and cytochrome c).
30
See Figure 1 for an overview of mitochondrial
function.
Mitochondria are the only organelle in mammalian
cells with their own genome. The ETC is coded by
both mitochondrial DNA (mtDNA) and nuclear DNA
(nDNA).
30 mtDNA contains 37 genes that code for
13 subunits of complexes I, III, IVand V, as well as the
machinery required to translate and transcribe
the mtDNA genes into ETC complex subunits. The
remainder of the ETC complex subunits are coded by
over 850 nDNA genes.
31 nDNA also codes for
mitochondrial enzymes that participate in carbohy-
drate and fatty acid oxidation. Thus, mutations in
either genome can impair mitochondrial function and
cause ETC complex deficiencies.
32
The ETC is the predominant source and the major
target of reactive oxygen species (ROS)
20,33 and is
protected from damage caused by ROS by a mito-
chondrial-specific superoxide dismutase and antiox-
idants such as glutathione (GSH).
33 Mitochondria
lack the enzymes to synthesize GSH and therefore
are dependent on cytosolic GSH production.
34,35 The
depletion of GSH in mitochondria makes cells more
vulnerable to oxidative stress and damage from ROS
originating from the mitochondria.
36 Additionally,
factors that increase ROS production (such as,
environmental toxicants, infections and autoimmune
disease) can directly and indirectly lead to impair-
ments in ETC activity,
27,37,38 deplete GSH,
37 and
activate mitochondrial and non-mitochondrial-
dependent biochemical cascades that result in pro-
grammed cell death (apoptosis).
39
Certain mammalian cells, such as neuronal and
non-neuronal brain cells, are very vulnerable to
oxidative stress (for example, damage caused by
ROS). The high rate of oxygen delivery and consump-
tion in the brain provides the oxygen molecules
necessary to generate ROS. The brain’s ability to
withstand oxidative stress is limited because of: (a) a
high content of substrates that are easily oxidized,
such as polyunsaturated fatty acids; (b) relatively low
levels of antioxidants, such as GSH and antioxidant
enzymes; (c) the endogenous generation of ROS via
several specific reactions; and (d) the endogenous
generation of nitric oxide (NO), a compound that
readily transforms into reactive nitrogen species.
Furthermore, the brain is very vulnerable to oxidative
damage because it contains non-replicating cells
which, once damaged, may be permanently dysfunc-
tional or committed to apoptosis.
37,39
The number of mitochondria in each cell depends
on the cellular energy demands. For example, low
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dria, while cells that require high energy demands,
such as muscle, liver, brain, cerebrovascular endothe-
lium and GI cells, have many mitochondria. Neural
synapses are areas of high energy consumption
40 and
are therefore especially dependent on mitochondrial
function.
41 Mitochondria are concentrated in the
dendritic and axonal termini where they have an
important role in ATP production, calcium home-
ostasis and synaptic plasticity.
42,43 Mitochondrial
dysfunction can lead to reduced synaptic neurotrans-
mitter release, and neurons that have high firing
rates, such as GABAergic interneurons, may be the
most adversely affected.
27 Mitochondria also have an
important role in cellular lipid metabolism, signaling
and repair.
44,45
MD was once thought to be uncommon but is
now considered the most recognized cause of meta-
bolic disease.
30 Despite increased recognition, the
prevalence of MD is probably underestimated.
46
The minimum birth prevalence of an ETC defect
with onset at any age has been estimated at 1 in 7634
individuals (B0.01%).
47 More than 100 mtDNA
deletions and over 150 mtDNA point mutations have
been described in individuals with MD.
29 MD has a
broad phenotypic presentation: children with MD can
have normal intelligence, mental retardation or
developmental delay.
48 Stressors, such as dehydra-
tion, fever and infection can lead to a functional
decline and neurodegenerative regression in indivi-
duals with MD.
49,50
The diagnosis of MD can be challenging, and is
based on several objective clinical, histological,
biochemical, molecular, neuroimaging and enzy-
matic findings. Several major diagnostic criteria are
used
51–55 to classify the probability of MD into: not
likely, possible, probable or definite; individuals
reaching the criteria for probable or definite are
typically considered to have MD. The diagnostic
criteria recognize several types of clinical presenta-
tions. These include primarily muscular or central
nervous system presentations or multisystem presen-
tations.
54,55 In addition, patients can present clinically
with one of the well-characterized mitochondrial
syndromes.
55 Other important diagnostic features
include abnormal histology (such as, ragged-red or
blue fibers in skeletal muscle, or skeletal muscle with
reduced cytochrome c oxidase or succinate dehydro-
genase staining, or electron microscopy demonstrat-
ing abnormal mitochondria or subsarcolemmal
mitochondrial accumulations), abnormal enzymology
(significantly impaired ETC activity), identification of
an mtDNA or nDNA mutation, abnormal neuroima-
ging and abnormal biochemical markers.
54,55
No reliable biomarker exists to identify all cases
of MD.
29 Biochemical markers of mitochondrial
dysfunction described in the literature include direct
(lactate, pyruvate, lactate-to-pyruvate ratio, ubiqui-
none, alanine, alanine-to-lysine ratio and acyl-carni-
tine) and indirect markers (creatine kinase (CK),
carnitine, aspartate aminotransferase (AST), alanine
aminotransferase (ALT) and ammonia).
25,29,54,56,57
Figure 1 Mitochondrial function and the electron transport chain (ETC). Abbreviations: ADP, adenosine diphosphate;
AKA, a-ketoglutarate; ATP, adenosine triphosphate; CoQ, co-enzyme Q; Cyt C, cytochrome c; e, electron; FAD, flavin adenine
dinucleotide; FADH2, reduced FAD; H, hydrogen; LCFA, long chain fatty acid; MCFA, medium chain fatty acid;
NAD, nicotinamide adenine dinucleotide; NADH, reduced NAD; OXPHOS, oxidative phosphorylation; PDC, pyruvate
dehydrogenase complex; SCFA, short chain fatty acid; TCA, tricarboxylic acid; I, complex I; II, complex II; III, complex III;
IV, complex IV; V, complex V. The red arrows denote the flow of electrons in the ETC. The color reproduction of this figure is
available on the html full text version of the article.
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For example, mitochondrial dysfunction impairs
aerobic respiration, leading to a reduction in TCA
cycle function resulting in an elevation in pyruvate
(see Figure 1). Pyruvate is metabolized to lactate and
alanine, leading to elevations in these metabolites
when pyruvate metabolism is impaired.
30,56 Inhibition
of the TCA cycle may result in an elevation of TCA
cycle intermediates. Inhibition of aerobic respiration
also impairs fatty acid b-oxidation, leading to eleva-
tions in the concentrations of acyl-carnitines. Further-
more, anaerobic respiration increases when aerobic
respiration is insufficient to meet cellular energy
demands. As lactate is one of the end-products of
anaerobic respiration, deactivation of aerobic respira-
tion further elevates lactate. As a result of this, the
measurement of plasma lactate can be helpful in the
initial workup of mitochondrial dysfunction.
30,54
However, lactate may be elevated only during illness,
or not at all, in children with MD.
48,57 In fact, normal
cerebrospinal fluid or serum lactate levels do not rule
out MD.
48,58
Indirect markers of mitochondrial function can also
be abnormal in MD. For example, depletion in total
and free carnitine can occur as a consequence of
excessive unprocessed fatty acids.
56 Ammonia may
be elevated for at least two reasons. First, under
anaerobic conditions, ammonia is produced when
adenosine monophosphate is broken down into
inosine monophosphate in order to replenish ATP.
Second, as the urea cycle is partially located in the
mitochondria, mitochondrial dysfunction can result
in secondary urea cycle dysfunction and an elevation
in ammonia. In addition, the integrity of certain
high-energy tissues, such as muscle and liver, can
be compromised from mitochondrial dysfunction,
resulting in elevations in indicators of tissue damage
such as CK, AST and/or ALT.
Mitochondrial dysfunction can be classified as
either primary or secondary.
29 Primary mitochondrial
dysfunction generally refers to mitochondrial dys-
function caused by a defect in a gene directly
involved in the function of mitochondrial systems
responsible for producing ATP, whereas secondary
mitochondrial dysfunction refers to other metabolic
or genetic abnormalities that impair the ability of
mitochondria to produce ATP. For example, metabo-
lites produced by toxic substances (for example,
environmental toxicants) or by the dysfunction of
other metabolic systems that are not specifically
involved in producing ATP (for example, increased
oxidative stress because of dysfunctional antioxidant
pathways) can interfere with the ability of mitochon-
dria to make ATP and lead to secondary mitochon-
drial dysfunction. Other reported causes of secondary
mitochondrial dysfunction include: certain medica-
tions;
29,59,60 enteric short chain fatty acids, such as
propionic acid;
61–65 elevated concentrations of tumor
necrosis factor-a;
66–68 cerebral folate deficiency;
69,70
malnutrition;
71 heme, vitamin B6, or iron deficien-
cies;
72 elevated NO;
73–75 GSH deficiency;
73 oxidative
stress;
36 or exposure to environmental toxicants, such
as heavy metals,
76–79 chemicals,
80 polychlorinated
biphenyls
81 or pesticides.
82,83 Some individuals have
findings consistent with MD but do not have an
identifiable genetic defect and/or do not meet full
criteria for definite or probable MD. It is possible that
these individuals have secondary mitochondrial
dysfunction
9,25,84,85 or may have an as yet unidentified
genetic abnormality. In this review article, we collate
evidence of both primary and secondary mitochon-
drial dysfunction in ASD.
Materials and methods
Search strategy
A prospective protocol for this systematic review was
developed a priori, and the search terms and selection
criteria were chosen in an attempt to capture
all pertinent publications. A computer-aided search
of PUBMED, Google Scholar, CINAHL, EmBase,
Scopus and ERIC databases from inception through
August 2010 was conducted to identify pertinent
publications using the search terms ‘autism’, ‘autis-
tic’, ‘Asperger’, ‘ASD’, ‘pervasive’, and ‘pervasive
developmental disorder’ in all combinations with
the terms ‘mitochondria’ OR ‘mitochondrial’ OR
‘lactic’ OR ‘lactate’ OR ‘pyruvate’ OR ‘pyruvic’ OR
‘ammonia’ OR ‘creatine kinase’ OR ‘oxidative phos-
phorylation’ OR ‘phosphorylation’ OR ‘carnitine’ OR
‘acyl-carnitine’ OR ‘fatty acid oxidation’ OR ‘alanine’
OR ‘respiratory chain’ OR ‘electron transport chain’
OR ‘energy’ OR ‘ATP’ OR ‘adenosine.’ The references
cited in identified publications were also searched to
locate additional studies. Figure 2 depicts the pub-
lications identified during the search process.
Study selection
One reviewer screened titles and abstracts of all
potentially relevant publications. Studies were
initially included if they (1) involved individuals
with ASD, and (2) reported at least one finding that
could indicate mitochondrial dysfunction. We also
included animal models of ASD with abnormal
energy pathways. Abstracts or posters from confer-
ence proceedings were included if published in
a peer-reviewed journal. After screening all records,
98 publications met inclusion criteria; both reviewers
then independently reviewed these articles. Articles
were excluded if they:
  Did not involve animals or humans or human cells
(for example, cellular models).
  Did not present new or unique data (such as, review
articles or letters to the editor).
  Presented duplicate data.
51,86,87
  Reported biochemical markers related to a
non-mitochondrial disorder
88–91 or cellular me-
chanism.
92,93
  Reported markers related to a known side effect
of a medication (for example, elevated ammonia
from valproic acid or rhabdomyolysis from ola-
nzapine).
94,95
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tegrative disorder.
A total of 68 publications,
5,23,25,28,35,48,49,58,61,62,64,65,
85,96–150 describing 65 unique studies, met inclusion
and exclusion criteria (see Figure 2), including three
sets of publications (6 publications total) that studied
the same population but provided slightly different
information.
28,119,120,132,133,144
Clinical characteristics in children with ASD compared
with controls
We reviewed all studies that included children with
ASD and presented biochemical markers that could
indicate mitochondrial dysfunction. A meta-analysis
was performed based on the information derived from
these studies. There are two types of measures
derived from the studies reviewed: prevalence values,
and comparisons of biomarker values between ASD
and control groups. A mean prevalence value was
computed by dividing the number of participants
with abnormal values for all studies by the number
of participants evaluated for all studies. A 95%
confidence interval (CI) was then calculated assuming
a Bernoulli distribution.
151 Several statistics were
computed for the comparisons of continuous biomar-
ker values between the ASD and control groups:
(a) means and variances were computed for both
groups; (b) the variances of the two groups were
compared using an F-ratio; (c) two different methods
were used to calculate the effect size; and (d) the
homogeneity statistic Q was calculated for each effect
size. Calculating effect size from populations that
have different variability can be problematic. There-
fore, we formally compared the variability in the
ASD and control groups using an F-ratio. Two
approaches are used to calculate the effect size for
populations with different variability. Glass et al.
152
Unique records identified
through database searching
(n = 716)
Records excluded
(n = 631)
Reasons:
496  Not related to ASD
101  ASD, not mitochondrial dysfunction
34    Related to Rett syndrome only
Total records identified
(n = 729)
Additional records identified
through other sources
(n = 13)
Records screened
(n = 729)
Publications included
in qualitative synthesis
(n = 68)
Full-text publications
assessed for eligibility
(n = 98)
Full-text publications excluded
(n = 30)
Reasons:
Review articles/letters, no new data
Publications with duplicate data
Related to non-mitochondrial cellular 
mechanisms
Related to non-mitochondrial disorders
Related to known medication side effects
2
4
2
3
19
Figure 2 Study flow chart. Abbreviation: ASD, autism spectrum disorder.
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control s.d. Others have suggested that a statistic,
such as the Hedge’s g, which uses the average sample
s.d., is a truer representation of the effect size.
153
Thus, we calculated both Glass’s D and Hedge’s g.
In addition, we calculated the homogeneity statistic
Q in order to test whether or not the effect sizes are
estimated from the same population means across
studies.
154
Clinical characteristics in children with ASD and
MD compared with controls
We also reviewed all studies that reported individuals
with ASD and a concomitant diagnosis of MD or
mitochondrial dysfunction (ASD/MD). All of these
studies described young children and adolescents,
with the oldest being 20 years old. Since these studies
spanned the entire childhood population, we refer to
this population as children. One case series reported
that the clinical characteristics of children with
ASD/MD are atypical of the general ASD popula-
tion.
25 However, that study
25 did not quantitatively
compare the characteristics of these two groups.
Therefore, we directly compared the prevalence of
characteristics of these two groups to determine if, in
fact, there are differences in the characteristics of
ASD/MD as compared with the general ASD popula-
tion, and, if so, which characteristics distinguish
these two groups. In order to perform this analysis, we
calculated the prevalence of commonly reported
clinical characteristics compiled from the studies of
children with ASD/MD as well as biochemical
and genetic markers of mitochondrial dysfunction
(see Table 3 and Supplementary Table S1). We
identified a total of 11 commonly reported clinical
characteristics of mitochondrial dysfunction (ataxia,
cardiomyopathy, fatigue/lethargy, GI abnormalities,
growth delay, hypotonia, male-to-female ratio, motor
delay, myopathy, regression and seizures). We then
compared the prevalence of these 11 characteristics
and abnormal biomarker values for children with
ASD/MD to two control groups: (a) the general
population of children with ASD, and (b) the general
population of children with MD. In order to deter-
mine the prevalence of these 11 clinical character-
istics of mitochondrial dysfunction in the general
population of children with ASD, we performed a
literature search for these characteristics in ASD. The
results of this search are found in the Supplementary
Table S2. In order to minimize bias, we only included
studies that had large sample sizes (96–987 children
per study; mean 359 children; total of 2870 children),
were published in high impact journals, and were
either epidemiology/population-based/longitudinal
studies
155–160 or large studies performed in academic
settings.
161,162 The prevalence of certain clinical
characteristics uncommon in the general ASD popu-
lation, such as ataxia, cardiomyopathy, fatigue/
lethargy, growth delay and myopathy could not be
calculated for this group because adequate studies
reporting these characteristics could not be identified.
For the prevalence of abnormal mitochondrial bio-
chemical markers in the general ASD population, we
used the prevalence results generated from our meta-
analysis (as listed in Table 1) for comparison. In order
to determine the prevalence of clinical characteristics
and biomarkers of mitochondrial dysfunction in the
general population of children with MD, we per-
formed a literature search for the above 11 clinical
characteristics as well as the biomarkers listed in
Table 3. The results of this search are found in the
Supplementary Table S3. To minimize bias, we only
included studies of MD that had large sample sizes
(25–133 children per study; mean 61 children; total of
428 children; one study
50 included 4 adults), were
published in high impact journals, and were either
population-based
163 or from large academic/referral
centers.
48,50,51,58,164–166 Chi-square analysis was used
to compare the prevalence rates between children
with ASD/MD and the prevalence rates in the two
Table 1 Pooled prevalence estimates for MD in ASD and for abnormal biomarkers of mitochondrial dysfunction in ASD
Studies Total
N
Overall prevalence Minimum
(%)
Maximum
(%)
General ASD population
Mitochondrial disease in ASD 3 536 5.0% (3.2%, 6.9%) 3.6 9.1
Elevated lactate 6 479 31.1% (27.0%, 35.3%) 17 77
Elevated pyruvate 2 110 13.6% (7.2%, 20.1%) 8 30
Elevated lactate/pyruvate ratio 1 192 27.6% (21.2%, 33.9%)
Elevated alanine 1 36 8.3% (0.0%, 20.1%)
Low total carnitine 1 30 90.0% (81.0%, 99.0%)
Elevated creatine kinase 1 47 46.8% (32.4%, 61.2%)
Elevated ammonia 1 80 35.0% (24.5%, 45.5%)
Elevated AST 1 147 45.6% (37.5%, 53.7%)
a
Elevated ALT 1 87 7.0% (0.5%, 13.5%)
Abbreviations: ALT, alanine aminotransferase; ASD, autism spectrum disorder; AST, aspartate aminotransferase;
MD, mitochondrial disease.
aThis value was found to be significantly higher than a control group.
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2 using the
observed frequencies of the ASD/MD group
and calculated the expected frequencies using the
prevalence rates in the comparison group. Since we
conducted 31 statistical tests, we controlled for
inflated alpha using the Bonferroni correction. Thus,
the statistical threshold was set at an alpha of 0.002
(0.05/31).
Results
The selected studies that reported clinical character-
istics and biomarkers of mitochondrial dysfunction
can be primarily separated into two groups: studies of
the general ASD population, and studies of children
with ASD/MD. In addition, two studies reported ASD
or features of ASD in children with MD,
48,58 and two
studies
105,112 examined correlations between biomar-
kers of mitochondrial dysfunction and the severity of
ASD symptoms. Several animal models of ASD
reported abnormalities in energy metabolism. Finally,
some studies reported specific treatments for mito-
chondrial dysfunction in ASD. These studies will be
discussed in subsections I through VI separately.
I. Studies examining the general ASD population
Table 1 outlines the prevalence estimates of MD and
abnormal mitochondrial biomarkers in the general
ASD population, while Table 2 outlines the mean
differences in mitochondrial biomarker values and
associated statistics in children with ASD as com-
pared with controls. The studies reviewed and
selected for individual biomarker calculations are
outlined in the Supplementary Table S4.
Prevalence of MD in ASD. Three studies examined
the prevalence of MD in ASD. Two were large
prospective studies
115,132 that examined the pre-
valence of MD using criteria as outlined by Bernier
et al.
55 and used an elevated plasma lactate to select
children to undergo further workup for MD (a muscle
biopsy). In these two studies, MD was diagnosed in
19%
115 to 43%
132 of ASD children with an elevated
lactate; however, only 56%
115 to 79%
132 of children
with an elevated lactate underwent a clinical workup
for MD. The third study was a retrospective case
series that examined 4194 individuals suspected
of having mitochondrial dysfunction; 276 were
reported to have autistic features and 14 of these
had MD
145 using the modified Walker criteria
outlined by Morava et al.
54 From these three studies,
meta-analysis (Table 1) demonstrated the overall
prevalence of MD in ASD was 5.0% (95% CI 3.2,
6.9%). However, it is likely that the prevalence of MD
is underestimated by these three studies because: (a)
individuals with a normal lactate did not undergo
a thorough evaluation for MD even though normal
lactate levels are found in some children with
ASD/MD;
25,49,143,147,150 (b) lactate alone was used in
two studies
115,132 to screen for MD, whereas additional
biochemical markers could have been used; and
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Molecular Psychiatry(c) children with known medical disorders, such
as septo-optic dysplasia, which could be related to
mitochondrial dysfunction,
167 were excluded from
testing for MD.
132 One study was particularly robust
as it was population based and examined the
prevalence of MD in children with ASD identified
from a population of 67795 children.
132,133
Prevalence of abnormal biochemical markers of
mitochondrial dysfunction in ASD. We reviewed
studies that examined the prevalence of abnorma-
lities in biochemical markers, which could indicate
mitochondrial dysfunction (Table 1). Studies that
used unusual methodology could not be included in
the analysis: one study examined the prevalence of
abnormalities in a combination of biomarkers rather
than just one biomarker;
23 another study examined
the prevalence of high (alanine and ammonia) and
low (free and total carnitine) biomarker values with
respect to the normal mean laboratory values instead
of the upper or lower limit of normal;
141 and one
study reported the prevalence of an elevated lactate-
to-pyruvate ratio only in a subgroup of ASD children
with elevated lactate.
132
Six studies
107,112,115,116,132,136 examining the preva-
lence of elevated lactate, two studies
116,136 examining
the prevalence of elevated pyruvate, one study
reporting the prevalence of lactate-to-pyruvate ratio
elevation,
115 and another study reporting the preva-
lence of elevated alanine
104 in the general population
of ASD were included in the meta-analysis. Almost
one-third of children with ASD had elevations in
lactate and/or the lactate-to-pyruvate ratio, while the
prevalence of pyruvate and alanine elevation was
lower. The prevalence of lactate elevation varied
widely from study to study. The reason for this is
not clear; however, variations in blood collection
technique are well known to cause differences in
lactate values. Unfortunately, many of the studies that
examined lactate, pyruvate or the lactate-to-pyruvate
ratio did not report the technique used to collect
blood (for example, fasting vs non-fasting, tourniquet
vs no tourniquet). Presumably, within each study,
the blood collection technique was consistent,
although failure to maintain such consistency could
result in an additional source of variation in these
measurements.
Indirect biochemical markers of mitochondrial
dysfunction also appear to be abnormal in the general
ASD population with a much higher prevalence than
the aforementioned direct biomarkers (see Table 1).
The prevalence of low total carnitine
112 and elevated
ammonia
116 were examined in one study each. Only
one study
85 looked at the prevalence of CK, AST and
ALT elevation, with the prevalence of AST elevation
being significantly higher as compared with a control
group (children with other neurological disorders
but not ASD). As these indirect markers are more
nonspecific than direct markers of mitochondrial
dysfunction, they could be abnormal because of other
problems.
Values of abnormal biochemical markers of
mitochondrial dysfunction in ASD. Table 2 outlines
the mean values (with CIs) of biochemical markers of
mitochondrial dysfunction, along with meta-analysis
statistics, for ASD and control groups. Five
studies
107,108,112,127,131 reported lactate values; one
study reported pyruvate values;
107 one study
reported carnitine values;
112 and one study exa-
mined ubiquinone concentrations.
110 Of note, one
study examined the correlation between carnitine
and lactate levels.
112 Additionally, one study
reported AST and ALT values,
85 and two studies
reported CK values.
106,127 Some studies could not be
included in the analysis because of limitations.
For example, one study reported significantly
higher mean plasma alanine and lysine in
children with ASD compared with controls,
109 and
another compared urinary alanine
103 between
ASD and control groups. However, both of these
studies
103,109 only provided the information
graphically. Another study reported a significantly
lower mean lysine in a subgroup of children with
ASD on a restricted diet, but not in those on an
unrestricted diet, compared with controls; this
study also reported elevated alanine prevalence
but not alanine values.
104 One study reported
significantly increased mean alanine transport in
fibroblasts from ASD children compared with
controls but did not report alanine values.
118
Finally, a longitudinal study reported abnormal
elevations in polyunsaturated long chain fatty
acids and/or saturated very long chain fatty acid-
containing ethanolamine phospholipids in children
with ASD compared with controls.
130 Although the
investigators in this latter study postulated that
one mechanism that could account for these
elevations was mitochondrial dysfunction,
130 these
abnormalities are not commonly accepted bio-
chemical markers of mitochondrial dysfunction.
Population variability, as indexed by the F-value,
was significantly greater in the ASD group as
compared with the control group for all biochemical
markers of mitochondrial dysfunction except ubiqui-
none, with the difference particularly marked for
pyruvate. This is consistent with the notion that
a subgroup of ASD children has abnormal mito-
chondrial biomarker values or that the range of
biochemical marker values of mitochondrial dysfunc-
tion is much larger for the ASD population in general,
suggesting that children with ASD might have a
spectrum of mitochondrial dysfunction.
The effect sizes calculated using either the Hedge’s
g or Glass’s D methods were large and statistically
significant for lactate (1.9-fold higher in ASD),
pyruvate (2.0-fold higher in ASD), carnitine (1.7-fold
lower in ASD) and ubiquinone (1.6-fold lower in
ASD) but not for CK, AST or ALT. Q was statistically
significant for the lactate Glass’s D effect size indicat-
ing that the effect size significantly varied across
studies. Individual Glass’s D effect sizes for lactate
were statistically significant for each study and varied
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127 to a maximum of 6.41.
107
Although the effect sizes for lactate varied across
studies, even the smallest effect size was quite robust.
Interestingly, one study reported a significant inverse
correlation between carnitine and lactate levels.
112
Prevalence of mtDNA abnormalities in ASD. In one
study, mtDNA deletions of varying length
(9.7–13.7kb) were found in 8 of 12 (67%) children
with ASD, but the specific genes affected were not
reported.
146 However, when specific mtDNA mutations
have been investigated in the general ASD population,
very few individuals with mutations have been found.
For example, one study of 810 individuals with ASD
that searched for mtDNA mutations (A3243A>G,
T8993T>G, T8993T>C and A8344A>G) only
identified two individuals (0.2%) with a mutation
affecting tRNA (A3243A>G).
135 Another study of 129
individuals with Asperger syndrome and 138 mothers
of individuals with Asperger syndrome searched
for the A3243A>G mutation, but no such mutation
was found.
134 Finally, in a study of 162 individuals
with ASD, no significant association was observed
between mtDNA haplogroup and ASD as compared
with a control population.
121
Prevalence of nDNA abnormalities in ASD. Three
nDNA genes associated with mitochondrial function
have been studied in the general ASD population. Two
studies examined the inner mitochondrial membrane
peptidase 2-like gene,
5,102 while 11 studies examined
gene expression and/or single-nucleotide polymor-
phisms in the SLC25A12 gene that codes for the
calcium-dependent mitochondrial aspartate/glutamate
carrier (AGC) isoform 1.
101,111,113–115,117,122,124–126,129 The
evidence for an association with either of these
genes was mixed and thus inconclusive, possibly
due to clinical and genetic heterogeneity between
studies and small sample sizes.
129 Additionally,
one study reported that several single-nucleotide
polymorphisms in the microtubule affinity-
regulating kinase 1 gene, a gene associated with
mitochondrial trafficking, were associated with
ASD, and microtubule affinity-regulating kinase 1
overexpression was demonstrated in postmortem
frontal cortex samples in individuals with ASD as
compared with healthy controls.
123 However, this
association has yet to be confirmed by additional
studies. Thus, to date, no conclusive association
between ASD and an nDNA gene associated with
mitochondrial function has been found.
mRNA expression in ASD. One recent study found
normal mRNA expression of the mitochondrial
complex I 75-kDa subunit in the general ASD
population.
100
In vitro studies of mitochondrial function and
mitochondrial oxidative stress in ASD. Three
controlled studies compared in vitro mitochondrial
function in lymphoblasts obtained from the Autism
Genetic Resource Exchange between individuals
with ASD and control individuals. In the first study,
the ASD group demonstrated depressed complex I
function, normal complex II activity and borderline
elevated complex IV activity compared with controls.
In addition, a higher mitochondrial maximal respi-
ratory rate was found in the ASD group and believed
to be a compensatory response to the depression
in complex I function.
119,120 In another lymphoblast
study, the mean baseline ATP concentration in
the ASD group was equivalent to controls, but
exposure to physiological concentrations of NO
reduced the mitochondrial membrane potential
in the ASD lymphoblasts more than in the control
lymphoblasts.
35 Finally, one study reported a reduced
mitochondrial membrane potential in ASD
mitochondria compared with controls.
128 These
studies support the notion that some individuals
with ASD manifest mitochondrial dysfunction and
compensatory mechanisms for such dysfunction.
Two studies using Autism Genetic Resource
Exchange samples measured markers of mitochon-
drial oxidative stress in vitro between individuals
with ASD and control individuals. In one study,
higher concentrations of ROS and reactive nitrogen
species were found in ASD mitochondria compared
with controls, consistent with increased generation of
mitochondrial free radicals.
128 In the second study, a
lower mean concentration of mitochondrial reduced
GSH was found in ASD lymphoblasts compared with
controls, consistent with a lower mitochondrial
GSH reserve. Additionally, exposure to ethylmercury
(thimerosal) led to a larger increase in the generation
of free radicals and a greater reduction in the ratio
of reduced GSH to the oxidized disulfide form of
glutathione (GSSG) in the ASD cells compared
with control cells.
35 These studies suggest that
some individuals with ASD manifest increased
oxidative stress that may originate from mito-
chondrial dysfunction.
Neuroimaging in ASD. In some individuals with
ASD, metabolites relating to brain bioenergetics
have been measured non-invasively using magnetic
resonance spectroscopy. One small magnetic reso-
nance spectroscopy study demonstrated significantly
decreased levels of phosphocreatine and esterified
end products (aATP, a-adenosine diphosphate,
dinucleotides and diphosphosugars) in the brains of
ASD individuals compared with controls.
105 Another
magnetic resonance spectroscopy study measured
N-acetyl-aspartate and lactate levels in the frontal
lobe, temporal lobe and the cerebellum, and found
significantly lower N-acetyl-aspartate levels in the
cerebellum of ASD children compared with controls
as well as elevated lactate in the frontal lobe of one
child with ASD.
108 A reduced concentration of brain
N-acetyl-aspartate may be a marker of mitochondrial
dysfunction,
168 although this is an area of debate.
169
However, changes in the other metabolites appear
consistent with abnormal brain bioenergetics.
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study, post-mortem brain oxidized (carbonylated)
mitochondrial protein content was nonsignificantly
(P=0.12) elevated by threefold in the ASD group
compared with controls with four of six (67%) ASD
brains demonstrating large elevations.
101
II. Studies examining children with ASD/MD
Eighteen studies reported a total of 112 children (up
to 20 years of age) with mitochondrial dysfunction or
MD and concomitant ASD (ASD/MD).
25,28,48,49,58,85,99,
115,132,133,136,139,140,142–145,147,149,150 Many (11 of 18, 61%)
of these studies did not specify the diagnostic criteria
used.
28,58,85,99,136,139,140,142,143,147,149 Only 8 of 18 (44%)
studies examined family history of MD with 3 of
8 studies (37.5%) noting a positive family history.
Three additional studies
137,138,148 that did not demon-
strate sufficient evidence to confirm mitochondrial
dysfunction or MD were not included in the analysis:
one study demonstrated elevations in several
acyl-carnitines in a child
148 consistent with a fatty
acid oxidation defect; another reported reduced free
carnitine and a mild ammonia elevation in two
children;
138 while the final study described elevated
urinary TCA cycle metabolites in two children.
137
Another study reported elevated lactate, pyruvate or
alanine in 13 of 28 children with ASD/MD but did not
report a prevalence for each biomarker, and therefore
the prevalence of these markers could not be
calculated nor included in the analysis.
49 Finally,
one study reported the prevalence of seven abnormal
mitochondrial histological findings, but it was
unclear from the study how many children had more
than one abnormal finding, and therefore the pre-
valence of each finding could not be calculated
nor included in the analysis.
25
Clinical characteristics as well as the biochemical
and genetic markers of mitochondrial dysfunction
reported in these 112 children with ASD/MD are
found in the Supplementary Table S1. Interestingly,
103 (92%) children were first diagnosed with
ASD before MD, 2 (2%) were diagnosed first with
MD before ASD,
140,143 while in 7 (6%) it was unclear
which diagnosis was made first.
48,58,136,142 Several
features of MD were not reported with enough
frequency to calculate the prevalence of such features
in children with ASD/MD. These features included
sleep abnormalities,
85 ammonia elevations,
140 carni-
tine abnormalities,
140 elevated alanine-to-lysine
ratio
85 and nDNA or chromosomal abnormal-
ities.
140,150 The prevalence of the clinical character-
istics and biomarkers of mitochondrial dysfunction
in ASD/MD are provided in Table 3. Table 3 also
presents prevalence estimates derived from the
selected comparison papers (reviewed in Materials
and Methods section) and statistically compares
children with ASD/MD with the general population
of ASD children and the general population of
children with MD. The prevalence of abnormal
organic acids and elevated alanine was relatively
high in ASD/MD, but adequate studies reporting these
markers could not be identified in the general
population of MD in order to compare these markers.
Comparisons between children with ASD/MD and the
general ASD population. Children with ASD/MD
demonstrated some distinct characteristics as
compared with the general population of children
with ASD. Developmental regression, seizures, motor
delay (such as, significantly delayed walking) and GI
abnormalities (such as, reflux or constipation) were
significantly more prevalent in children with ASD/
MD as compared with the general ASD population. It
is notable that children with ASD/MD demonstrated
a relatively high prevalence of motor delay (51%),
regression (52%), fatigue/lethargy (54%), ataxia
(58%) and GI abnormalities (74%). Although motor
delay was significantly more common in ASD/MD,
the prevalence of hypotonia was not significantly
different between children with ASD/MD and the
general ASD population. Lactate and pyruvate, but
not the lactate-to-pyruvate ratio or CK, were elevated
with a significantly higher prevalence in children
with ASD/MD as compared with children in the
general ASD population. Interestingly, the ASD/MD
population had a significantly more balanced male-to-
female ratio than children from the general ASD
population.
Comparisons between children with ASD/MD and the
general MD population. The prevalence of male
gender, developmental regression, seizures, hypo-
tonia, cardiomyopathy and myopathy was not
significantly different between MD groups with and
without ASD. However, the prevalence of fatigue/
lethargy, ataxia, GI abnormalities and elevated lactate
was significantly higher in children with ASD/MD as
compared with the general population of MD. The
prevalence of an abnormal brain imaging scan
was significantly lower in children with ASD/MD as
compared with the general MD population.
The prevalence of complex I, II, III, IV, V and
multiple complex deficiencies was not significantly
different between children with MD with and without
ASD, nor was the prevalence of elevated citrate
synthase or mtDNA abnormalities. However, the
prevalence of abnormal histology on light microscopy
was significantly more common in the general
population of MD compared with ASD/MD. The most
common complex deficiency in children with ASD/
MD was in complex I (53%). Children with ASD/MD
were also significantly more likely to have normal
ETC activity. Of note, complex V activity was only
reported in five studies of ASD/MD,
48,49,58,132,139
although it was abnormal in a relatively high
percentage in some studies.
132,139
Mitochondrial histology and ultrastructural
abnormalities in children with ASD/MD. One case
series reported several mitochondrial histological
abnormalities, including variations in muscle fiber
size, regenerating fibers, atrophic fibers, muscle
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reduced cytochrome oxidase staining.
25 Only three
studies reported ‘ragged-red fibers’ in children with
ASD/MD,
25,99,139 which is not surprising as the
presence of ragged-red fibers is an unusual finding
in children, even in those with MD.
30
The ultrastructural abnormality most commonly
reported was mitochondrial proliferation.
25,28,49,138–140,142,144
Some studies described specific ultrastructural
abnormalities, such as mitochondria with abnormal
cristae,
139 inclusions,
139 and abnormally shaped and
sized mitochondria.
25,139,149 However, these features
were not reported with enough frequency to calculate
accurate prevalence values or to compare them with
the general population of MD.
Genetic abnormalities in children with ASD/
MD. Only 24 of 112 (21%) children with ASD/MD
had an mtDNA, nDNA or chromosomal abnormality.
Table 4 reviews the mtDNA abnormalities reported in
ASD/MD, including mtDNA depletion, mutations
and deletions. mtDNA abnormalities were tested
in 87 of 112 (78%) children with ASD/MD with
20 of 87 (23%) demonstrating an abnormality
(see Supplementary Table S1). mtDNA depletion
and deletions were reported in three
49,142,145 and
five individuals with ASD/MD,
139 respectively.
Pathogenic mtDNA mutations were described in 12
children with ASD/MD.
25,99,142,145,147 Interestingly, no
abnormalities were found in the majority (77%) of
children with ASD/MD in which mtDNA was
examined.
Additionally, one study reported an nDNA muta-
tion (SCO2) in an individual with ASD/MD.
145 This
mutation could adversely affect the synthesis of
cytochrome c oxidase.
170 Two chromosomal abnorm-
alities were reported to be associated with ASD/MD:
two children had an inverted duplication of 15q11–
q13
140, and one child had a deletion in 5q14.3.
150
However, the relationship between these chromo-
somal abnormalities and ASD or mitochondrial
dysfunction is unclear.
Table 3 Prevalence of clinical characteristics and mitochondrial biomarkers in children with ASD/MD with comparison with
the general ASD and MD populations
ASD/MD General ASD General MD
% N % w
2 P % w
2 P
Male 61 72 81 18.7 <0.0001 58 0.26 0.61
Developmental regression 52 83 25 32.3 <0.0001 60 2.2 0.14
Seizures 41 86 11 79.1 <0.0001 33 2.48 0.11
Hypotonia 62 55 51 2.6 0.10 67 0.62 0.43
Fatigue/lethargy 54 61 19 48.6 <0.0001
Ataxia 58 19 13 34.0 <0.0001
Growth delay 21 73
Motor delay 51 79 9 170.1 <0.0001
GI abnormalities 74 35 20 63.8 <0.0001 39 18.0 <0.0001
Cardiomyopathy 24 38 26 0.1 0.79
Myopathy 0 12 11 1.5 0.22
Elevated lactate 78 50 31 51.6 <0.0001 54 12.4 <0.001
Elevated pyruvate 45 22 14 17.6 <0.0001
Elevated lactate/pyruvate ratio 43 23 28 2.6 0.11
Abnormal organic acids 36 36
Elevated creatine kinase 34 29 47 1.96 0.16
Elevated alanine 32 28
Abnormal brain imaging 23 69 70 72.6 <0.0001
Normal ETC activity 16 69 3 40.1 <0.0001
Abnormal complex I 53 96 45 2.48 0.12
Abnormal complex II 9 65 8 0.09 0.76
Abnormal complex III 30 96 31 0.04 0.83
Abnormal complex IV 20 97 34 8.47 0.004
Abnormal complex V 23 44 12 5.0 0.03
Multiple complex deficiency 36 59 27 2.43 0.12
Elevated citrate synthase 24 17 44 2.76 0.10
Abnormal light microscopy 18 49 81 126.4 <0.0001
mtDNA abnormality 23 87 16 3.17 0.08
Abbreviations: ASD, autism spectrum disorder; GI, gastrointestinal; MD, mitochondrial disease; mtDNA, mitochondrial
DNA.
Prevalence was compared across groups using w
2 test with an a-threshold of 0.002. Significant differences are highlighted
in gray.
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dysfunction with ASD symptoms
In one study of 11 individuals with ASD and
11 normal controls, abnormal levels of brain markers
of mitochondrial function measured by magnetic
resonance spectroscopy (including phosphocreatine,
aATP, a-adenosine diphosphate, dinucleotides and
diphosphosugars) significantly correlated with the
severity of language and neuropsychological deficits
in the ASD group but not in the control group.
105
In another study of 30 children with ASD, those with
severe ASD (as measured by the Childhood Autism
Rating Scale) had both significantly lower carnitine
and higher lactate concentrations than those with
mild or moderate ASD.
112 Additional studies are
needed to evaluate these apparent correlations.
IV. Prevalence of ASD or autistic features in MD
Two retrospective case series of children with MD
reported ASD or features of ASD in some of the
children;
48,58 one other case series presented dupli-
cate data and was not included in the analysis.
51 The
overall prevalence of ASD or ASD features in children
with MD was calculated to be 4.6% (95% CI 0.3,
8.9%). However, since these studies were not popula-
tion based, they may not accurately reflect the true
prevalence of ASD in children with MD.
V. Animal models of ASD with abnormal function of
the energy pathway
Several animal models of ASD exhibit mitochondrial
dysfunction. For example, a recent rat model of ASD
demonstrated that the administration of propionic
acid, a fermentation end product of enteric bacteria,
induced mitochondrial dysfunction and led to certain
brain, behavioral and metabolic changes consistent
with ASD, including features such as repetitive
behaviors, social interaction problems, hyperactivity,
oxidative stress, lowered GSH levels, microglial
activation and altered carnitine levels.
61,62,64,65 In a
mouse model, mutations in the SLC25A12 gene,
a susceptibility gene for ASD, which codes for a
mitochondrial AGC that is crucial for supporting
oxidative phosphorylation and ATP production,
resulted in neurofilamentous accumulations in neu-
rons and myelination deficits. Interestingly, the
myelin deficits could be reversed by the administra-
tion of pyruvate in vitro.
97 The maternal ubiquitin
protein ligase E3A deficiency mouse is a model of
Angelman’s syndrome, a syndrome that frequently
includes ASD features. Recently, this mouse model
was reported to have abnormal mitochondrial mor-
phology and a partial oxidative phosphorylation
defect in complex III in the hippocampal region.
171
The MECP2-null mouse is a mouse model of Rett
syndrome, a neurodegenerative disorder that includes
ASD features. This mouse demonstrates decoupling
of the respiratory complexes and overexpresses the
nuclear gene for ubiquinol-cytochrome c reductase
core protein 1, a gene that codes for a subunit of ETC
complex III.
172 Creatine helps to maintain adequate
ATP levels in tissues with high energy requirements
and a specific creatine transporter is required for the
uptake of creatine by cells.
173 A mouse model of a
creatine transporter gene mutation (SLC6A8) reported
seizure activity and autistic-like behavior.
98 Finally, a
mouse model of neuronal glucose transporter isoform
3 deficiency demonstrated certain autistic character-
istics including seizure activity, abnormal social
behavior and stereotypies.
96 Glucose transporter iso-
form 3 mediates the uptake of glucose by neurons
and impaired glucose transporter isoform 3 activity
Table 4 Number of cases of mtDNA abnormalities reported in the general population of children with ASD and in children
with ASD/MD
MD MD unknown Positive family history
mtDNA depletion 3 1
mtDNA deletions 5 8
mtDNA mutations
tRNA 7 2 2
3243A>G 4 2 2
Complex I 3
Primary LHON 2
POLG 2
Summary for mtDNA mutations in MD above Reference
3397A>G (complex I) and 4295A>G (tRNA) Weissman et al.
25
3243A>G MELAS 2, POLG 2, LHON 2 Scaglia et al.
145
3243A>G 2 Pons et al.
142
G8363A (tRNA) Graf et al.
147
G10406A (tRNA) Pancrudo et al.
99
Abbreviations: ASD, autism spectrum disorder; LHON, Leber Hereditary Optic Neuropathy; MELAS, mitochondrial
myopathy, encephalopathy, lactic acidosis and stroke syndrome; MD, mitochondrial disease; mtDNA, mitochondrial DNA;
POLG, polymerase gamma; tRNA, transfer RNA.
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depletion.
174
VI. Treatment of mitochondrial dysfunction in ASD
Several studies suggested that nutritional supple-
ments and/or antioxidants may be beneficial in some
children with ASD who have MD or abnormal
biomarkers of mitochondrial function. Carnitine
was the most commonly noted supplement to be
helpful.
28,85,130,138,140,150 Along with carnitine, some
investigators reported clinical improvements with
co-enzyme Q10
85,143,150 and high doses of B-vitamins,
including thiamine or riboflavin.
85,140,150 Cerebral
folate deficiency was described in one child with
ASD/MD,
49 and specific treatment with folinic
acid and a milk-free diet has been reported to result
in significant improvements in ASD symptoms in
children with cerebral folate deficiency.
175,176 Unfor-
tunately, a majority of the reviewed studies did not
report on any potential treatments for mitochondrial
dysfunction in ASD.
Discussion
In this systematic review and meta-analysis, we
examined the evidence for an overlap between ASD
and mitochondrial dysfunction and/or MD. From our
analysis, MD was reported in 5.0% of children with
ASD. We also found that there is a rather high
prevalence of abnormal values in direct (that is,
lactate, pyruvate and lactate-to-pyruvate ratio) and
indirect (that is, carnitine, ammonia, CK and AST)
biochemical markers of mitochondrial dysfunction in
the general population of children with ASD, and that
children with ASD, as a group, have significantly
abnormal values for direct (that is, lactate, pyruvate
and ubiquinone) and indirect (that is, carnitine)
biochemical markers of mitochondrial dysfunction
compared with controls. The variability in the values
of these biochemical markers was, for the most part,
significantly larger in the ASD group as compared
with the control groups, indicating that the ASD
population manifests a wide variety of values of
biochemical markers for mitochondrial dysfunction.
Two studies reported significant correlations between
markers of mitochondrial dysfunction and autism
severity. Additionally, there appears to be a high
prevalence of mtDNA deletions, but not pathogenic
mtDNA mutations, in the general ASD population,
and studies of nDNA have not found consistent
abnormalities. In vitro studies with limited sample
sizes have identified mitochondrial dysfunction,
lower mitochondrial GSH reserve and higher mito-
chondrial oxidative stress in the cells of individuals
with ASD compared with controls. Neuroimaging
studies have also reported abnormalities in biomar-
kers of energy metabolism in children with ASD. One
study reported a trend for higher levels of brain
oxidized mitochondrial protein content in ASD
compared with controls. Although many of the
studies included in this review have limitations, their
cumulative findings suggest that there is evidence for
mitochondrial dysfunction in ASD, or at the least, in a
subset of children with ASD.
Our review also demonstrates that children with
ASD/MD have distinct characteristics as compared
with the general population of children with ASD and
have many similarities to the general population of
children with MD. Abnormalities in mitochondrial
histology and ultrastructure were reported in some
children with ASD/MD. Surprisingly, only a rela-
tively modest percentage (21%) of children with
ASD/MD had a genetic abnormality that might
account for mitochondrial dysfunction. Although
two studies suggested that children with ASD or
features of ASD constitute a small proportion of
the general MD population,
48,58 certain limitations
of these studies indicate they may not accurately
reflect true prevalence. Several animal models of ASD
reported mitochondrial dysfunction. A limited num-
ber of studies reported various improvements in
children with ASD and mitochondrial dysfunction
with certain treatments. Below we will discuss some
important aspects of this review, limitations of our
analyses, and important avenues for further study.
Children with ASD/MD: a distinct subgroup of children
with ASD or a distinct MD syndrome?
Mitochondrial dysfunction is the most common
metabolic abnormality associated with ASD.
115,177
Meta-analysis of three studies
115,132,145 indicated that
the prevalence of MD in ASD was 5.0% (95% CI 3.2,
6.9%), which is significantly higher than found in the
general population (B0.01%),
47 indicating that an
association between ASD and MD is likely, at least in
a subgroup of individuals with ASD.
25 However, this
5% prevalence is most likely an underestimate of the
true prevalence of MD in individuals with ASD since
these studies excluded children from testing for MD
who had either normal lactate or medical disorders
potentially related to mitochondrial dysfunction.
Additionally, two of these three studies exclusively
used lactate to identify children to be fully assessed
for MD.
115,132 This latter limitation appears to be
common in the reviewed studies, as only a few
studies evaluated ASD children who had a normal
lactate for MD.
142,143,147,150 Using only lactate as a
screening test for MD may miss some individuals
with MD. In the future, the development of sensitive
and specific non-invasive or minimally invasive
methods for identifying MD, such as the routine
examination of mitochondrial function in lympho-
cytes, should make the identification of the true
prevalence of MD in ASD children more realistic.
In general, MD and mitochondrial dysfunction may
be underrecognized in the general ASD population,
9
especially because the identification of children
with ASD and concomitant mitochondrial dysfunc-
tion can be quite challenging. For example, bio-
chemical markers may be abnormal only during
illness,
25,49,142,143,147,150 tissue mitochondrial hetero-
plasmy can result in mitochondrial dysfunction being
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99,139 and known
genetic defects are not commonly found in ASD/MD.
Of note, routine laboratory testing to screen for
mitochondrial dysfunction in children with ASD is
not often performed,
132 perhaps because previous
investigators have suggested that mitochondrial
dysfunction is rare in ASD
177 and should only be
considered when there is a family history of MD or
neurological features suggestive of MD.
134,142 How-
ever, our review indicates that many children with
ASD/MD do not have a family history of MD or
neurological features that distinguish them from the
general ASD population.
25,132,133,142 In fact, the phe-
notypic presentation of mitochondrial dysfunction in
ASD is quite broad, ranging from significant to no
neurological problems,
25,139,142,147 with some investi-
gators describing children with ASD/MD as being
indistinguishable from other children with ASD and
others describing them as atypical for ASD.
25,132,133,142
Furthermore, our review suggests that some ASD
children with abnormal markers of mitochondrial
function do not meet definite or probable criteria for
MD but rather may have a mild form of mitochondrial
dysfunction, such as partial complex deficiencies,
that may not be considered significant by some
clinicians.
9,25,35,85
Interestingly, two studies reported a significant
correlation between biochemical markers of mito-
chondrial dysfunction and the severity of ASD
symptoms.
105,112 This correlation suggests that mito-
chondrial dysfunction exists on a continuum rather
than in a discrete subgroup of ASD children. Such a
notion is consistent with many of the findings in this
review, including the much higher prevalence of
abnormal biochemical markers of mitochondrial
dysfunction as compared with the prevalence of MD
in the general ASD population, and the particularly
high variability in biochemical markers of mitochon-
drial dysfunction in the general ASD population.
Clearly, additional studies are needed to better define
the clinical and biochemical characteristics of ASD/
MD children and to determine if a discrete ASD/MD
subgroup exists or whether mitochondrial dysfunc-
tion in ASD is better represented on a continuum.
Our review of the 112 children with ASD/MD
reported in the medical literature found several
distinct clinical characteristics in this group, such
as developmental regression, seizures, motor delay, GI
abnormalities, and a higher prevalence of elevated
lactate and pyruvate, as compared with the general
ASD population. Additionally, children with ASD/
MD had many similarities to the general population of
children with MD, including the prevalence of male
sex, regression, seizures, hypotonia, cardiomyopathy,
myopathy and ETC abnormalities. This suggests that
these clinical characteristics are more likely due to
mitochondrial dysfunction than to ASD. Of course,
this might also be an artifact of using diagnostic
criteria for MD to define children with ASD/MD.
However, other clinical characteristics which were
significantly more prevalent in children with ASD/
MD as compared with the general population of MD,
such as fatigue/lethargy, ataxia, GI abnormalities and
elevated lactate, are unlikely to be due simply to the
use of diagnostic criteria. From our review, it also
appears unlikely that these abnormalities reported in
ASD/MD are due to factors, such as poor diet, anxiety
or GI symptoms. Although three studies did attempt
to identify MD from the general ASD population,
these studies did not fully define the clinical or
biochemical characteristics of the individuals identi-
fied.
115,132,145
The finding of a significantly elevated prevalence
(74%) of GI abnormalities (such as reflux, constipa-
tion, diarrhea and inflammation) in children with
ASD/MD compared with both children with ASD and
children with MD is intriguing and deserves further
study. Recently, increased awareness of GI problems
in ASD has been noted
12,178 and the findings of this
review suggest that GI abnormalities in ASD may
be related, in part, to mitochondrial dysfunction.
Interestingly, mitochondrial dysfunction has been
demonstrated in a mouse model of inflammatory
bowel disease, and carnitine supplementation re-
versed both the metabolic and clinical abnormalities
in this model.
179 It is also possible that some
metabolites originating from the GI tract, such as
propionic acid produced by Clostridia, other enteric
short chain fatty acids and certain cytokines might act
as mitochondrial toxins. These factors might also
contribute to seizure activity and our analysis found
that seizures were significantly more common in
ASD/MD compared with the general population of
ASD. Given the high energy demands of both the
GI tract and cerebrovascular endothelium, mitochon-
drial dysfunction may also contribute to barrier
dysfunction in the brain and GI tract in ASD.
Additionally, as mitochondria have an important role
in lipid metabolism, previous reports of abnormalities
in lipid metabolism
180,181 and lipid peroxidation
182 in
some individuals with ASD could be due to mito-
chondrial dysfunction. Further studies are needed
to determine the role of mitochondrial dysfunction in
barrier dysfunction, lipid abnormalities, GI dysfunc-
tion and seizure activity in ASD.
Interestingly, in the reviewed studies, no child with
ASD/MD presented with a classic mitochondrial
syndrome. Some experts have reported that autistic
features are relatively common in children with
MD in conjunction with a global neurological syn-
drome.
183 However, the two studies that examined the
presence of ASD characteristics in the general MD
population did not support this assertion. It is
possible that children with MD do not present with
the typical symptoms of ASD. Alternatively, it may be
that features of ASD are not specifically examined or
recognized in many children who are diagnosed
with MD, or that a potentially high severity of the
presenting symptoms of MD does not trigger a
differential diagnosis of ASD. These possibilities are
supported by the finding that only 2% of children
with ASD/MD were diagnosed with MD before ASD.
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specific syndrome within children with MD, but
further studies will be needed to better define
common clinical symptoms within larger cohorts of
children with ASD/MD.
Regression in children with mitochondrial dysfunction
and ASD
Twelve studies reported a regression in developmen-
tal milestones in ASD children who had MD or
abnormal biochemical markers of mitochondrial
function.
23,25,49,85,132,137,139–142,147–149 In these studies,
regression was noted in several areas, including
language, motor skills, eye contact, play skills, social
interaction and receptive skills. In one case series
of 25 children with ASD/MD, unusual patterns of
regression, such as multiple regressions (9 children),
regression with catabolic stress (7 children) and
regression after age 3 (6 children) were noted.
25 In
some studies, factors associated with regression
included illnesses
25,140,142 and fever.
49,142 For example,
in one case series of 28 children with ASD/MD,
regression was reported in 17 children (61%), with a
majority (12/17, 71%) experiencing regression with a
fever >1011F, including 4 of 12 (33%) who developed
regression with fever following routine vaccination.
49
Regression after routine vaccination was also reported
in another child who developed ASD/MD after a post-
vaccination fever.
25,85 However, these latter three
studies
25,49,85 noted the important role of childhood
vaccinations in preventing life threatening diseases.
Interestingly, some children with ASD have clinical
improvements during fever,
184 suggesting that there
are subgroups of children with ASD that respond
differently to fever and that it is probably not the fever
itself, but the underlying physiological process lead-
ing to fever that is related to regression in children
with ASD.
It should be noted that, in each of the reviewed
studies, it is not clear if mitochondrial dysfunction
contributed to or caused the reported regression. Our
analysis indicated that the prevalence of regression
was significantly higher in children with ASD/MD as
compared with the general population of children
with ASD (52 vs 25%). Given that regression in
individuals with MD is known to occur with stressors
such as dehydration, fever and infection,
50 and that
the prevalence of regression in children with ASD/
MD is approximately double that of the general
population of ASD, it is likely that the regression
reported in at least a subset of children with ASD/MD
is related to mitochondrial dysfunction. This is
significant because early identification of children
with underlying MD who might be at risk of under-
going regression into ASD because of a metabolic
stressor could lead to prophylactic measures to
prevent the development of ASD, or at least minimize
the severity of ASD symptoms once acquired.
Although such a subset of children is likely to
constitute a limited proportion of the general ASD
population, given the high prevalence of ASD,
the absolute number of individuals who could be
protected is likely to be significant. One caveat is the
assumption that these children had identifiable MD
before the regression, which is empirically unproven
because the MD was not identified until after the
regression.
Secondary mitochondrial dysfunction in ASD
A majority (79%) of the children with ASD/MD
identified in this review did not possess a genetic
etiology that might account for mitochondrial dys-
function. Although a yet unidentified genetic defect
may be present in some of these cases, secondary
mitochondrial dysfunction is likely.
9,85 Biochemical
abnormalities reported in some children with
ASD could contribute to secondary mitochondrial
dysfunction. For example, several studies have
documented a significantly lower mean GSH concen-
tration
110,130,185–189 and a lower mitochondrial GSH
reserve
35 in children with ASD as compared with
controls. GSH depletion is associated with impaired
mitochondrial function
73 and increased ROS produc-
tion.
36 Increased ROS can impair mitochondrial
function
36,190 and may be particularly significant in
individuals with ASD because they have been shown,
as a group, to be under higher oxidative stress and
have reduced levels of antioxidants as compared with
controls.
35,110,130,185–189,191 Furthermore, GSH protects
mitochondria against the adverse effects of tumor
necrosis factor-a,
36 a pro-inflammatory cytokine that
can inhibit mitochondrial function.
66,67 This might be
particularly important since studies have reported
higher tumor necrosis factor-a in lymphocytes,
192
cerebrospinal fluid
193 and brains
194 of individuals
with ASD as compared with controls.
In one reviewed study, exposure to physiological
concentrations of NO reduced the mitochondrial
membrane potential in ASD cells more than in control
cells,
35 suggesting that ASD mitochondria are more
vulnerable to the adverse effects of NO. Several studies
have reported a significantly higher mean concentra-
tion of NO in ASD individuals as compared with
controls,
110,195–197 making it possible that individuals
with ASD are not only more vulnerable to NO but also
have higher baseline NO concentrations. These two
factors could act synergistically to cause significant
mitochondrial impairment in individuals with ASD.
Abnormalities in synaptic transmission reported in
ASD could also contribute to secondary mitochon-
drial dysfunction. For example, an imbalance in the
excitatory (glutamatergic) and inhibitory (GABAergic)
neurotransmitter systems has been implicated
in the pathogenesis of ASD, with a relative increase
in the glutamatergic neurotransmitter system.
198
In vitro glutamate exposure has been shown to inhibit
mitochondrial b-oxidation
130,199 as well as generate
ROS
200 and deplete GSH.
130,200 In one reviewed study,
in vitro glutamate plus malate exposure adversely
affected mitochondrial function in cells from indivi-
duals with ASD to a greater extent as compared with
control cells.
119
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cury (thimerosal) led to a larger increase in free
radical generation and a greater reduction in the ratio
of reduced GSH to GSSG in ASD cells compared with
control cells.
35 These findings suggest that mitochon-
dria from children with ASD may be more vulnerable
to damage from environmental toxicants than mito-
chondria from typically developing children.
35 In this
context, exposures to environmental toxicants could
contribute to secondary mitochondrial dysfunction in
some children with ASD.
9,201 For example, in vitro
exposure to diesel exhaust particles has been shown
to inhibit mitochondrial function,
80 and elevated
environmental concentrations of diesel exhaust
particles have been associated with ASD.
202 Other
environmental toxicants that inhibit mitochondrial
function and have been associated with ASD include
mercury,
76,77,202–204 lead,
78,205–207 cadmium,
79,202 poly-
chlorinated biphenyls
81,208 and pesticides.
83,209–211
Interestingly, some investigators have suggested
that mtDNA deletions reported in some children with
ASD may be secondary to elevated levels of ROS
caused by environmental factors.
146
Abnormal calcium signaling, which has been
implicated in ASD,
212,213 may also contribute to
secondary mitochondrial dysfunction.
26,214 For exam-
ple, the mitochondrial AGC, which is coded by
SLC25A12, is involved in the malate-aspartate re-
duced nicotinamide adenine dinucleotide shuttle and
is activated, in part, through calcium signaling.
215
One mouse model
97 reported myelination deficits
in mice with mutations in SLC25A12 and several
studies
111,113,122,124–126 reported single-nucleotide
polymorphisms in SLC25A12 were associated with
ASD, although this association was not found in every
study.
114,115,117,129,216 However, in one study of six
individuals with ASD and six controls, increased
calcium levels and mitochondrial AGC transport rates
were observed in all six ASD brains. The removal of
calcium by a chelator led to a larger drop in mean
AGC transport rate in the ASD group compared with
controls.
101 This finding suggests that abnormal
calcium signaling contributes to AGC dysfunction in
the brains of some individuals with ASD and may
lead to mitochondrial dysfunction.
A recent rat model of ASD demonstrated that the
administration of propionic acid induced mitochon-
drial dysfunction and led to certain behavioral and
biochemical features of ASD, such as repetitive
behaviors, social interaction problems, hyperactivity,
oxidative stress, lowered GSH levels and altered
carnitine levels.
61,62,64,65 In addition, Clostridia,a n
anaerobic, spore forming Gram-positive rod bacteria,
is known to produce propionic acid
61 and a derivative
of propionic acid recovered in the urine of ASD
individuals has been reported as a marker of
Clostridia.
217 Furthermore, significantly elevated
concentrations of Clostridia in the GI tract have
been reported in ASD children compared with
controls
218–220 with improvements noted with vanco-
mycin treatment in some children.
221,222 Additional
studies examining the roles of propionic acid and
Clostridia in ASD are needed.
Currently, it is unclear if these endogenous and
exogenous factors reported in some individuals with
ASD contribute to secondary mitochondrial dysfunc-
tion or ASD symptoms, or if these factors are merely
epiphenomena. However, these factors represent
potential pathways that may impair mitochondrial
function and increase the vulnerability of mitochon-
dria to damage. Furthermore, a combination of these
factors may lead to synergistic adverse effects on
mitochondrial function. In this context, mitochon-
drial dysfunction could worsen a vulnerable system
that is already under oxidative stress, resulting in an
increase in the formation of ROS. As increased ROS
can cause further damage to already damaged mito-
chondria and can directly impair mitochondrial
function,
190 adding mitochondrial dysfunction to a
metabolic system that is already under high oxidative
stress can result in the initiation of a vicious cycle
that progressively impairs cellular function, leading
to neurodegeneration, regression or failure of cogni-
tive systems to properly develop.
27 Clearly, further
studies are needed to examine a possible link between
the effects of these potentially detrimental substances
and mitochondrial dysfunction in vivo. Although the
effects of the environment on mitochondrial dysfunc-
tion are becoming increasingly recognized,
223 and
environmental pollutants, particularly environmental
mercury, have been associated with an increased
likelihood of ASD in epidemiological studies,
202–204
the mechanism of such environmental toxicants
for increasing the risk of ASD has not been well
studied in vivo. Clearly, mitochondrial function is a
ripe area of research when investigating the biological
mechanism(s) of action of environmental toxicant
exposures and indigenous abnormalities associated
with ASD.
Mitochondrial dysfunction and synaptic
transmission in ASD
Given the association between ASD and mitochon-
drial dysfunction, it is possible that mitochondrial
dysfunction might have a role in the development,
pathogenesis or severity of ASD. For example,
mitochondrial dysfunction could be specifically
detrimental to synaptic transmission because synap-
tic function is highly dependent on mitochondrial
function.
41 Furthermore, single-nucleotide poly-
morphisms in microtubule affinity-regulating
kinase 1
123 and SLC25A12
122 reported in some
individuals with ASD could alter synaptic plasticity
and mitochondrial movement along dendrites.
Such possibilities would be consistent with recent
studies that have implicated synaptic dysfunction in
ASD.
224
Mitochondrial dysfunction can also lead to reduced
synaptic neurotransmitter release, particularly in
neurons with high firing rates, such as GABAergic
interneurons.
27 Since GABAergic neurons are inhibi-
tory, they may be especially important between
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development corresponds to an over-production
in excitatory neurotransmitters and receptors.
225,226
Thus, without proper GABAergic neuronal function,
the brain may be highly susceptible to excitotoxicity
during this developmental period. Interestingly, this
is the age range when regression most commonly
occurs in ASD.
227 Additional studies are needed
to investigate these possibilities.
Identification of mitochondrial dysfunction in children
with ASD
In the reviewed studies, the workup for MD varied
widely from study to study. Lactate was by far the most
commonly studied biochemical marker of mitochon-
drial dysfunction in ASD. Both lactate and pyruvate
demonstrated a high prevalence of being abnormal in
ASD, were significantly elevated in the general ASD
population as compared with controls, and had a
significantly higher prevalence of being abnormal in
ASD/MD as compared with the general ASD popula-
tion. Carnitine also had a high prevalence of being
abnormal in ASD and was significantly depressed in
the general ASD population as compared with controls.
However, it is difficult to determine the utility of
certain biomarkers (alanine, ammonia, carnitine, ubi-
quinone, alanine-to-lysine ratio and acyl-carnitine
panel) for identifying mitochondrial dysfunction in
the general population of children with ASD because
the number of reports describing these biomarkers in
ASD/MD was limited. Despite the lack of information
that was derived from published reports, these bio-
markers should be strongly considered when screening
for MD in children with ASD because abnormal alanine
is a recognized marker of MD
54 and ammonia,
ubiquinone and an acyl-carnitine panel can help
identify mitochondrial dysfunction when lactate is
not elevated.
57,228,229 Further studies are needed to
systematically examine the sensitivity, specificity and
predictive value of these markers for diagnosing
MD in the general ASD population.
Figure 3 outlines a suggested algorithm for screen-
ing for mitochondrial dysfunction in ASD. In order to
standardize the collection and optimize the diagnosis
of MD, some investigators have recommended obtain-
ing laboratory tests in the morning while fasting
38,56
and repeating abnormal tests to verify true abnormal-
ities.
38 Obtaining laboratory values when the patient
is sick or under physiological stress may also increase
the sensitivity of detecting mitochondrial dysfunc-
tion.
48,57 Furthermore, a specific MD can be diagnosed
by identifying a known mtDNA or nDNA gene
abnormality using molecular testing that requires
only a blood draw. However, in the reviewed studies,
a genetic defect was not identified in the majority of
children with ASD/MD. When a genetic marker
cannot be identified, more invasive testing, such as
a muscle or skin biopsy can be used to confirm MD.
Although a muscle biopsy is more invasive than
a skin biopsy, detailed pathological examination of
the muscle can be particularly helpful in confirming
MD. Although most reviewed studies reported ETC
function, fatty acid oxidation pathways can also be
examined if a skin biopsy is performed. A reduction
in ETC function in two tissues can make the diagnosis
of MD more definitive. Thus, if a muscle biopsy
is performed, it is straightforward and advantageous
to perform a skin biopsy at the same time.
In children with abnormal markers of mitochon-
drial function, it is important to consider other causes
besides MD. Elevated CK in ASD can occur
with muscular dystrophy
89,91 or rhabdomyolysis.
95
Elevated ammonia in ASD has been associated with
valproate administration
94 and urea cycle disorders.
90
Furthermore, false-positive elevations in biochemical
markers (especially lactate) are possible, especially if
the child struggles during the blood draw or if the
sample is not properly processed.
56 Elevations in
lactate can also be found in disorders unrelated to
MD.
230 Finally, restrictions in diet may be important
considerations in testing for MD as one study reported
a significantly lower mean lysine in ASD children on
a restricted diet, but not in those on an unrestricted
diet, compared with controls.
104
Three studies examined the prevalence of MD in
ASD and the workups for MD in these studies reflect
some of the difficulties that are common in the
evaluation of MD. For example, in two of these
studies, only 56%
115 to 79%
132 of ASD children with
an elevated lactate were tested for MD. This likely
reflects the variability in the willingness of families to
allow their child with ASD to undergo invasive
testing in light of the fact that the treatment for MD
is limited (see below) and the yield of an invasive
workup is variable. In addition, in these two studies,
19%
115 to 43%
132 of ASD children with an elevated
lactate were found to have MD when fully assessed;
this finding reflects the specificity of lactate for
identifying MD in ASD and the variability in the
yield of MD workups in various clinics.
It is noteworthy that older guidelines do not
recommend a routine metabolic workup in children
with ASD.
231 However, newer reviews on the biolo-
gical basis of ASD have outlined the growing number
of mitochondrial and non-mitochondrial metabolic
disorders associated with ASD.
201,232–234 Clearly, more
studies are needed to develop sensitive and specific
diagnostic techniques for MD in children with ASD.
However, until such diagnostic techniques are avail-
able, we believe that all children with ASD should be
screened for MD given: (a) the high prevalence of
abnormal markers of mitochondrial function in ASD
compared with controls; (b) the relatively high
prevalence of MD in ASD; (c) some children with
ASD who have MD can be phenotypically indis-
tinguishable from typical children with ASD; and (d)
the potential clinical significance of MD in children
with ASD.
Treatment and management
There is no known cure for MD. However, the
treatment and management of MD attempt to minimize
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to mitochondria, treat organ dysfunction that results
from mitochondrial dysfunction, and provide supple-
mentation of important mitochondrial cofactors and
ROS scavengers. It is essential that individuals with
MD avoid dehydration, prolonged fasting and/or
illnesses that could result in metabolic decompensa-
tion.
50 Certain common medications, such as acet-
aminophen, and anesthetics should be avoided and
an anesthesiologist familiar with MD should be
consulted if anesthesia is necessary.
60
Several studies suggested that treatment with
mitochondrial cofactor supplementation, including
antioxidants, co-enzyme Q10, carnitine and B-vita-
mins may improve mitochondrial function and
behavior in some children with ASD. A therapeutic
trial of mitochondrial cofactors and antioxidants may
be reasonable in children with ASD/MD given the fact
that: (a) oxidative stress is associated with impaired
mitochondrial function;
190 (b) antioxidant supple-
mentation in individuals with MD increases GSH
levels;
235 (c) mitochondria are dependent on cytosolic
GSH production;
34,35 and (d) these compounds are
generally recognized as safe.
9 For example, methylco-
balamin and folinic acid have been reported to
significantly increase GSH concentrations in children
with ASD and appear to improve certain autistic
behaviors.
185,187 Several other antioxidants, including
vitamin C,
236 carnosine
237 and galantamine
238–240
have also been reported to significantly improve
autistic behaviors. Carnitine may be particularly
helpful in children with ASD because carnitine
deficiency has been implicated in ASD,
112,141 some
studies have reported improvements with the use of
carnitine in ASD
28,85,130,138,140,150 and carnitine may
lower the toxicity
241 of a potential Clostridial meta-
bolite (a derivative of propionic acid) that has been
recovered in the urine of some individuals with
Fasting morning labs:
Lactate
Pyruvate
Carnitine (free and total)
Acyl-carnitine panel
Quantitative plasma amino acids
Ubiquinone
Ammonia
CK
AST/ALT
CO2, glucose
Consider repeating labs if
sick or under stress
Labs normal
Clinical history:
Family history of MD
Regression
Seizures
Fatigue/lethargy
Ataxia
Motor delay
GI abnormalities
Cardiomyopathy
Consider skin/muscle biopsy
or referral to specialist
Consider
Targeted blood testing:
Start empiric treatment:
Carnitine
Coenzyme Q10
B vitamins
Antioxidants
Repeat fasting labs
Labs abnormal
Rule out other causes
Normal 
Abnormal
No other causes
DNA testing
negative
mtDNA deletions or point mutations
nDNA gene mutations
Figure 3 Suggested screening for mitochondrial dysfunction in ASD. Abbreviations: ASD, autism spectrum disorder; ALT,
alanine aminotransferase; AST, aspartate aminotransferase; CK, creatine kinase; GI, gastrointestinal; MD, mitochondrial
disease; mtDNA, mitochondrial DNA; nDNA, nuclear DNA.
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217 However, despite the potential therapeutic
nature of these compounds, systematic studies doc-
umenting the efficacy of these treatments for mito-
chondrial dysfunction in children with ASD are
generally lacking.
Limitations of this review and meta-analysis
Many of the reviewed studies suffered from limita-
tions. For example, most of the studies that examined
the prevalence of abnormal biochemical markers of
mitochondrial function in ASD were probably sus-
ceptible to referral bias. In fact, there was only one
study that was population based to prevent referral
bias.
132,133 In addition, most of the studies examining
the abnormal prevalence or the difference in the
values of biochemical markers were based on a
limited sample size (that is, <100 patients) and some
studies did not contain a control group and/or were
retrospective in nature.
Additionally, studies describing children with
ASD/MD were based on small case series or isolated
case reports and demonstrated variability in the
protocols used for selecting children for MD workup,
collecting biochemical markers of mitochondrial
dysfunction, and defining MD. In fact, only 39% of
the ASD/MD studies reviewed noted the criterion
used for diagnosing MD. The lack of a standard
criterion for diagnosing MD likely resulted in a
heterogeneous population with varying degrees of
mitochondrial dysfunction. In addition, many of the
characteristics found to be more prevalent in ASD/
MD are features of the criteria generally used to
diagnose MD, suggesting that the clinical criteria
could have influenced which children were selected
to undergo evaluation for MD. Furthermore,
most studies only examined a limited number of
biochemical markers of mitochondrial dysfunction
and contained too few participants to examine the
interrelationship(s) between these markers. More
studies are needed to determine how well the
reviewed biochemical markers of mitochondrial dys-
function correlate with actual MD in children with
ASD. For example, comparing biochemical markers
(such as lactate and carnitine) with measurements
of ETC activity, mtDNA abnormalities and other
mitochondrial abnormalities would be helpful in
examining this further.
Two of the three studies examining the prevalence
of MD in children with ASD used only lactate
to identify candidates for further workup.
115,132 It is
likely that many of the ASD/MD case studies also
used lactate as the primary biomarker to pursue a
further workup for MD. Since cases have been
reported in which biomarkers other than lactate are
elevated in MD, it is likely that studies which
identified candidates for additional workup of MD
using only lactate as a criterion overlooked some
patients with MD. In addition, it is unclear whether
using strict criteria for diagnosing MD may eliminate
ASD children who have mild mitochondrial dysfunc-
tion such as partial complex deficiencies.
In this review, we compared the prevalence of
several clinical and biochemical characteristics be-
tween children with ASD/MD and two other clinical
groups: children with MD and the general ASD
population. The characteristics of these other clinical
groups were estimated by a separate literature review.
It is possible that some of the studies of the general
MD population may have included a percentage of
children with unrecognized ASD, thereby biasing the
prevalence of certain characteristics in the childhood
MD population toward the ASD/MD population.
Although this percentage appears to be low from our
review of the childhood MD literature, there have not
been any studies specifically designed to estimate
ASD prevalence in childhood MD. Similarly, some
studies of the general ASD population may have
included children with unrecognized MD, leading
to a similar bias. The most significant limitation in
defining and comparing the group of children with
ASD/MD with other groups is the uncertainty regard-
ing whether there is a well-definable subset of ASD
children with MD or whether mitochondrial dysfunc-
tion in ASD is best represented on a continuum, with
a subset of ASD children having mild or moderate
mitochondrial dysfunction that does not fully meet
the criteria for MD.
Conclusions
This systematic review and meta-analysis found that
abnormal biochemical markers of mitochondrial
function are relatively common in the general
population of children with ASD and that a relatively
high percentage of children with ASD (B5%) have
MD. However, it is unclear whether the general
population of children with ASD is best characterized
as having a distinct subgroup with mitochondrial
dysfunction or as having a spectrum of mitochondrial
dysfunction of differing severity. In this review, we
examined the common characteristics of all reported
cases of ASD/MD and compared these characteristics
with the general ASD population and to the general
population of children with MD. This analysis
suggested that the ASD/MD cases, as a group, had a
greater prevalence of several clinical characteristics as
compared with the general population of ASD, and a
similar prevalence to children with MD in many
clinical and biochemical characteristics. However, an
examination of the reviewed studies indicates that
the methods for identifying and diagnosing MD need
better characterization before a more precise group of
ASD/MD can be defined.
At this point, it is not clear if mitochondrial
dysfunction contributes to the development or patho-
genesis of ASD or if it is merely an epiphenomenon
of ASD. Several metabolic abnormalities and/or
exposures to environmental toxicants could result in
secondary mitochondrial dysfunction in children
with ASD, or these factors could worsen mild
mitochondrial dysfunction in some children, trans-
forming mild dysfunction into more severe dysfunc-
tion. Some children demonstrated regression into
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Molecular PsychiatryASD and MD following fever, suggesting children
who develop MD may be vulnerable to external
factors causing regression into ASD in children who
may already have existing, but unidentified, MD. This
suggests that it is important for children with MD to
be identified early in life. Identification and long-
itudinal evaluation of the development of such
individuals will allow investigators to better under-
stand how mitochondrial dysfunction may be related
to the development of ASD. In the meantime, until
further studies can be performed, a reasonable
approach to ASD includes a workup for MD and
possible treatment with antioxidants and mitochon-
drial cofactors.
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